FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing 
RA'ANANA, Israel, and NEW YORK, Sept. 05, 2017 -- UroGen Pharma Ltd. (NASDAQ:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that Ron Bentsur, the Company’s Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference on Monday, September 11, 2017 at 2:35 p.m. EDT. The conference will be held in New York, NY.
A live audio webcast of the presentation will be available by visiting the Investors section of the UroGen Pharma website at http://investors.urogen.com. An archived replay of the webcast will be available on the Company's website for 90 days following the live presentation.
About UroGen Pharma Ltd.
UroGen Pharma (NASDAQ:URGN) is a clinical-stage biopharmaceutical company developing advanced non-surgical treatments to address unmet needs in the field of urology, with a focus on uro-oncology. The Company has developed RTGel, a proprietary sustained release, hydrogel-based formulation for potentially improving therapeutic profiles of existing drugs. UroGen Pharma's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen Pharma's lead product candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade UTUC and bladder cancer. UroGen Pharma has offices located in both Ra’anana, Israel and New York, NY, USA.
CONTACTS: UroGen Pharma Ltd. Gary Titus Chief Financial Officer [email protected] 646-768-9531 Or Burns McClellan, Inc. Steve Klass [email protected] 212-213-0006
